ALLMedicine™ Chronic Anemia Center

Mar 14th, 2023 - BACKGROUND Gastric antral vascular ectasia (GAVE) is a rare clinical entity that presents with acute upper-gastrointestinal bleeding or chronic anemia. It is characterized by endoscopic watermelon appearance of the stomach. It is usually associate...

Mar 10th, 2023 - Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant vascular disease. ENG and ACVRL1 gene variants account for up to 96% of all cases, while the remaining cases are caused by SMAD4 or GDF2 variants, or by currently undiscovered mu...

Feb 28th, 2023 - There is considerable controversy regarding optimal management of patients with paraesophageal hiatus hernia (pHH). This survey aims at identifying recommended strategies for work-up, surgical therapy, and postoperative follow-up using Delphi meth...

Feb 18th, 2023 - HbSC disease is the second most frequent sickle cell disease (SCD) genotype after HbSS. Globally, approximately 55,000 newborns are delivered annually with HbSC disease, with the highest HbC gene frequency in West Africa. In Ghana, 40% of adults a...

Feb 14th, 2023 - Sickle cell disease (SCD) is a devastating inherited hemoglobin disorder characterized by recurrent episodes of pain and chronic hemolytic anemia. Chronic anemia contributes to multi-organ damage and decreased life expectancy in SCD. However, ther...

Feb 14th, 2023 - Sickle cell disease (SCD) is a devastating inherited hemoglobin disorder characterized by recurrent episodes of pain and chronic hemolytic anemia. Chronic anemia contributes to multi-organ damage and decreased life expectancy in SCD. However, ther...

Jan 11th, 2023 - Sickle cell disease (SCD) is a genetic blood disorder that has profound effects on the brain. In the presence of chronic anemia, the brain microvasculature dilates in order to maintain adequate oxygen delivery to the tissue. As cerebral blood flow...

Nov 21st, 2022 - To establish and maintain a CDA registry (CDAR): a comprehensive registry of subjects with the diagnosis of any type of congenital dyserythropoietic anemia in North America. Subjects and their physicians have expressed interest in participating in...

Oct 21st, 2022 - Blood is a living tissue composed of specific structures, each with distinct functions. Blood transfusion is a tissue or even organ transplantation. Unnecessary blood transfusion should not be done, and the missing component should be replaced in ...

Aug 4th, 2022 - The most recent International Classification of pulmonary arterial hypertension (PHA) include Hemoglobinopathies in Class I. At present there is no determination of the prevalence of this disease in a large population of thalassemic patients follo...

Apr 14th, 2022 - Treatment with mitapivat (Pyrukynd) increased hemoglobin levels and decreased hemolysis in patients with pyruvate kinase (PK) deficiency who did not require regular blood transfusions, the randomized ACTIVATE trial showed. For the phase III study'...

Dec 3rd, 2021 - The FDA has granted priority review to the supplemental biologics license application (sBLA) for luspatercept-aamt (Reblozyl) for the treatment of anemia in adults with non–transfusion dependent (NTD) β-thalassemia. The European Medicines Agency h...

Jun 13th, 2021 - The first-in-class erythroid maturation agent luspatercept (Reblozyl) is already approved for the treatment of anemia in adult patients with beta thalassemia who require red blood cell (RBC) transfusions. Now it has also shown to be beneficial for...

Dec 5th, 2020 - As hematology/oncology fellows, we work with colleagues from multiple specialties. However, the majority of our interactions are with the internal medicine service, so here we will help you to maximize the quality of your interactions with interna...

Dec 4th, 2020 - Diane McDowell, MD Results from the pivotal phase III BELIEVE trial, which supported the FDA approval of luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) tra...